An optimized approach in the synthesis of imatinib intermediates and analogues

被引:13
作者
Kinigopoulou, M. [1 ]
Filippidou, M. [1 ]
Gogou, M. [1 ]
Giannousi, A. [1 ]
Fouka, P. [1 ]
Ntemou, N. [1 ]
Alivertis, D. [2 ]
Georgis, C. [1 ]
Brentas, A. [1 ]
Polychronidou, V. [1 ]
Voulgari, P. [1 ]
Theodorou, V. [1 ]
Skobridis, K. [1 ]
机构
[1] Univ Ioannina, Dept Chem, GR-45110 Ioannina, Greece
[2] Univ Ioannina, Dept Biol Applicat & Technol, GR-45110 Ioannina, Greece
关键词
PHENYLAMINO-PYRIMIDINE PAP; TYROSINE KINASE INHIBITOR; CHRONIC MYELOID-LEUKEMIA; FACILE TOTAL-SYNTHESIS; BCR-ABL; SELECTIVE INHIBITOR; ANTITUMOR-ACTIVITY; WILD-TYPE; KIT; DERIVATIVES;
D O I
10.1039/c6ra09812f
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
We revisited the classical synthetic procedure for imatinib synthesis providing an improved and optimized approach in the preparation of a series of new imatinib analogues. The proposed methodology effectively overcomes certain problematic steps, saves time and labor, provides a very high yield and purity and has the potential to be used for the synthesis of many analogues. The formation of the desired guanidine salt 4, one of the key steps to the imatinib synthesis, was proceeded almost quantitatively by the reaction of the hydrochloride of the suitable aniline 3 with excess of molten cyanamide, without any solvent. Pure arylamine intermediates 6a-d were obtained quantitatively in a short reaction time after reduction of the nitro group of the intermediate pyrimidines 5a-d with hydrogen over the Adam's catalyst. In addition, the application of this optimized approach can be extended in the synthesis of nilotinib and its analogues intermediates.
引用
收藏
页码:61458 / 61467
页数:10
相关论文
共 44 条
[1]   Proteome Changes Induced by Imatinib and Novel Imatinib Derivatives in K562 Human Chronic Myeloid Leukemia Cells [J].
Arvaniti, Katerina ;
Papadioti, Anastasia ;
Kinigopoulou, Maria ;
Theodorou, Vassiliki ;
Skobridis, Konstantinos ;
Tsiotis, Georgios .
PROTEOMES, 2014, 2 (03) :363-381
[2]   Glivec (ST1571, Imatinib), a rationally developed, targeted anticancer drug [J].
Capdeville, R ;
Buchdunger, E ;
Zimmermann, J ;
Matter, A .
NATURE REVIEWS DRUG DISCOVERY, 2002, 1 (07) :493-502
[3]   BAY 43-9006 inhibition of oncogenic RET mutants [J].
Carlomagno, F ;
Anaganti, S ;
Guida, T ;
Salvatore, G ;
Troncone, G ;
Wilhelm, SM ;
Santoro, M .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2006, 98 (05) :326-334
[4]   Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases [J].
Carter, TA ;
Wodicka, LM ;
Shah, NP ;
Velasco, AM ;
Fabian, MA ;
Treiber, DK ;
Milanov, ZV ;
Atteridge, CE ;
Biggs, WH ;
Edeen, PT ;
Floyd, M ;
Ford, JM ;
Grotzfeld, RM ;
Herrgard, S ;
Insko, DE ;
Mehta, SA ;
Patel, HK ;
Pao, W ;
Sawyers, CL ;
Varmus, H ;
Zarrinkar, PP ;
Lockhart, DJ .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2005, 102 (31) :11011-11016
[5]   2-aminothiazole as a novel kinase inhibitor template.: Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1-piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (Dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor [J].
Das, Jagabandhu ;
Chen, Ping ;
Norris, Derek ;
Padmanabha, Ramesh ;
Lin, James ;
Moquin, Robert V. ;
Shen, Zhongqi ;
Cook, Lynda S. ;
Doweyko, Arthur M. ;
Pitt, Sidney ;
Pang, Suhong ;
Shen, Ding Ren ;
Fang, Qiong ;
de Fex, Henry F. ;
McIntyre, Kim W. ;
Shuster, David J. ;
Gillooly, Kathleen M. ;
Behnia, Kamelia ;
Schieven, Gary L. ;
Wityak, John ;
Barrish, Joel C. .
JOURNAL OF MEDICINAL CHEMISTRY, 2006, 49 (23) :6819-6832
[6]   The synthesis of Bcr-Abl inhibiting anticancer pharmaceutical agents imatinib, nilotinib and dasatinib [J].
Deadman, Benjamin J. ;
Hopkin, Mark D. ;
Baxendale, Ian R. ;
Ley, Steven V. .
ORGANIC & BIOMOLECULAR CHEMISTRY, 2013, 11 (11) :1766-1800
[7]   Nilotinib: A Second-Generation Tyrosine Kinase Inhibitor for the Treatment of Chronic Myelogenous Leukemia [J].
DeRemer, David L. ;
Ustun, Celalettin ;
Natarajan, Kavita .
CLINICAL THERAPEUTICS, 2008, 30 (11) :1956-1975
[8]   Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. [J].
Druker, BJ ;
Sawyers, CL ;
Kantarjian, H ;
Resta, DJ ;
Reese, SF ;
Ford, JM ;
Capdeville, R ;
Talpaz, M .
NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (14) :1038-1042
[9]   Protein kinases as targets for anticancer agents: from inhibitors to useful drugs [J].
Fabbro, D ;
Ruetz, S ;
Buchdunger, E ;
Cowan-Jacob, SW ;
Fendrich, G ;
Liebetanz, J ;
Mestan, J ;
O'Reilly, T ;
Traxler, P ;
Chaudhuri, B ;
Fretz, H ;
Zimmermann, J ;
Meyer, T ;
Caravatti, G ;
Furet, P ;
Manley, PW .
PHARMACOLOGY & THERAPEUTICS, 2002, 93 (2-3) :79-98
[10]   Molecular mechanisms of resistance to imatinib in Philadelphia-chromosome-positive leukaemias [J].
Gambacorti-Passerini, CB ;
Gunby, RH ;
Piazza, R ;
Galietta, A ;
Rostagno, R ;
Scapozza, L .
LANCET ONCOLOGY, 2003, 4 (02) :75-85